Immunome, Inc. (NASDAQ:IMNM) Receives $28.83 Average PT from Analysts

Shares of Immunome, Inc. (NASDAQ:IMNM) have received an average rating of “Buy” from the seven ratings firms that are covering the firm, MarketBeat reports. Seven analysts have rated the stock with a buy rating. The average 1-year target price among brokerages that have covered the stock in the last year is $28.83.

A number of research firms have commented on IMNM. Wedbush reissued an “outperform” rating and set a $33.00 target price on shares of Immunome in a research report on Friday, October 25th. Stephens initiated coverage on shares of Immunome in a report on Friday, November 8th. They set an “overweight” rating and a $30.00 price objective on the stock. Finally, Piper Sandler lowered their target price on Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a report on Thursday, November 14th.

Immunome Trading Down 5.0 %

Shares of Immunome stock opened at $10.54 on Friday. The stock’s fifty day moving average price is $12.01 and its 200-day moving average price is $13.20. The firm has a market cap of $657.88 million, a P/E ratio of -1.30 and a beta of 1.83. Immunome has a 12 month low of $8.97 and a 12 month high of $30.96.

Insider Activity at Immunome

In related news, CTO Philip Tsai bought 21,000 shares of the company’s stock in a transaction on Thursday, November 21st. The shares were bought at an average price of $9.43 per share, with a total value of $198,030.00. Following the transaction, the chief technology officer now owns 21,000 shares in the company, valued at approximately $198,030. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Robert Lechleider purchased 15,805 shares of the business’s stock in a transaction on Thursday, November 21st. The shares were bought at an average price of $9.48 per share, for a total transaction of $149,831.40. Following the purchase, the insider now directly owns 15,805 shares in the company, valued at $149,831.40. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders have acquired 102,862 shares of company stock valued at $978,045 in the last ninety days. Corporate insiders own 8.60% of the company’s stock.

Institutional Trading of Immunome

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. FMR LLC increased its holdings in shares of Immunome by 0.3% in the third quarter. FMR LLC now owns 4,224,700 shares of the company’s stock valued at $61,765,000 after purchasing an additional 13,757 shares during the period. Janus Henderson Group PLC boosted its position in Immunome by 10.3% in the third quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company’s stock valued at $50,971,000 after buying an additional 324,614 shares during the last quarter. Marshall Wace LLP increased its holdings in Immunome by 228.5% in the 2nd quarter. Marshall Wace LLP now owns 1,713,325 shares of the company’s stock worth $20,731,000 after buying an additional 1,191,774 shares during the period. Geode Capital Management LLC raised its position in Immunome by 13.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,207,455 shares of the company’s stock worth $17,657,000 after buying an additional 144,557 shares during the last quarter. Finally, Victory Capital Management Inc. lifted its stake in Immunome by 48.1% during the 3rd quarter. Victory Capital Management Inc. now owns 730,785 shares of the company’s stock valued at $10,684,000 after acquiring an additional 237,497 shares during the period. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.